Literature DB >> 22386719

Left ventricular remodeling in preclinical experimental mitral regurgitation of dogs.

A Ray Dillon1, Louis J Dell'Italia, Michael Tillson, Cheryl Killingsworth, Thomas Denney, John Hathcock, Logan Botzman.   

Abstract

Dogs with experimental mitral regurgitation (MR) provide insights into the left ventricular remodeling in preclinical MR. The early preclinical left ventricular (LV) changes after mitral regurgitation represent progressive dysfunctional remodeling, in that no compensatory response returns the functional stroke volume (SV) to normal even as total SV increases. The gradual disease progression leads to mitral annulus stretch and enlargement of the regurgitant orifice, further increasing the regurgitant volume. Remodeling with loss of collagen weave and extracellular matrix (ECM) is accompanied by stretching and hypertrophy of the cross-sectional area and length of the cardiomyocyte. Isolated ventricular cardiomyocytes demonstrate dysfunction based on decreased cell shortening and reduced intracellular calcium transients before chamber enlargement or decreases in contractility in the whole heart can be clinically appreciated. The genetic response to increased end-diastolic pressure is down-regulation of genes associated with support of the collagen and ECM and up-regulation of genes associated with matrix remodeling. Experiments have not demonstrated any beneficial effects on remodeling from treatments that decrease afterload via blocking the renin-angiotensin system (RAS). Beta-1 receptor blockade and chymase inhibition have altered the progression of the LV remodeling and have supported cardiomyocyte function. The geometry of the LV during the remodeling provides insight into the importance of regional differences in responses to wall stress. Copyright Â
© 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22386719     DOI: 10.1016/j.jvc.2012.01.012

Source DB:  PubMed          Journal:  J Vet Cardiol        ISSN: 1760-2734            Impact factor:   1.701


  7 in total

1.  Intravenous administration of allogeneic Wharton jelly-derived mesenchymal stem cells for treatment of dogs with congestive heart failure secondary to myxomatous mitral valve disease.

Authors:  Vicky K Yang; Dawn M Meola; Airiel Davis; Bruce Barton; Andrew M Hoffman
Journal:  Am J Vet Res       Date:  2021-06       Impact factor: 1.156

2.  Severity of mitral regurgitation predicts risk of death or cardiac transplantation in children with idiopathic dilated cardiomyopathy.

Authors:  Amit Patange; Ronald Thomas; Robert D Ross
Journal:  Pediatr Cardiol       Date:  2013-08-06       Impact factor: 1.655

3.  A graph theoretic approach for computing 3D+time biventricular cardiac strain from tagged MRI data.

Authors:  Ming Li; Himanshu Gupta; Steven G Lloyd; Louis J Dell'Italia; Thomas S Denney
Journal:  Med Image Anal       Date:  2016-06-11       Impact factor: 8.545

Review 4.  The renin-angiotensin-aldosterone system and its suppression.

Authors:  Marisa K Ames; Clarke E Atkins; Bertram Pitt
Journal:  J Vet Intern Med       Date:  2019-02-26       Impact factor: 3.333

5.  Pharmacokinetics of single dose sildenafil orally administered in canine models of chronic embolic pulmonary hypertension.

Authors:  Ryota Akabane; Touko Sato; Atsushi Sakatani; Mizuki Ogawa; Masayoshi Nagakawa; Hirosumi Miyakawa; Yuichi Miyagawa; Hiroyuki Tazaki; Naoyuki Takemura
Journal:  J Vet Med Sci       Date:  2020-02-26       Impact factor: 1.267

6.  Pathologic Manifestations on Surgical Biopsy and Their Correlation with Clinical Indices in Dogs with Degenerative Mitral Valve Disease.

Authors:  J Lee; M Mizuno; T Mizuno; K Harada; M Uechi
Journal:  J Vet Intern Med       Date:  2015-07-27       Impact factor: 3.333

Review 7.  Review of Diagnostic and Therapeutic Approach to Canine Myxomatous Mitral Valve Disease.

Authors:  Giulio Menciotti; Michele Borgarelli
Journal:  Vet Sci       Date:  2017-09-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.